Senior Scientist I, Cancer Immunology
Revolution Medicines
Summary
As a key player in our Cancer Immunology team, you will use your immuno-oncology expertise to help advance Revolution Medicines' assets in preclinical and clinical development.
Job description
Responsibilities
- Design, develop, validate and execute in vitro, in vivo, and ex vivo studies to address key translational questions and support immuno-oncology biomarker plans.
- Identify, evaluate and implement emerging technologies to enhance translational biomarker discovery and mechanistic understanding.
- Drive reverse translation efforts by formulating and testing hypotheses derived from clinical finding as appropriate to inform clinical development plans.
- Stay abreast of advances in tumor immunology and immunotherapy, identifying novel combination strategies and contributing to preclinical evaluation.
- Analyze, interpret, and communicate complex data effectively across internal cross-functional teams and at external scientific meetings.
- Represent Revolution Medicines at scientific conferences and other external engagements.
Required Skills, Experience and Education
- Ph.D. in immunology, cancer biology, or a related discipline, with deep expertise in tumor immunology, immuno-oncology biomarkers, and/or immunotherapy.
- Proven track record of research excellence, evidenced by high-impact publications.
- Expertise in in vivo model design to evaluate the efficacy and mechanisms of action of therapeutic agents and enable biomarker discovery, both internally and via contract research organizations.
- Strong technical expertise in immunology techniques including multi-parameter flow cytometric analyses, primary human cellular/tissue-based functional assays, cell biology and molecular biology to guide/inform mechanism of action and biomarker discovery.
- Strong problem-solving skills and ability to independently oversee scientific projects, rigorously analyze and interpret scientific data while maintaining attention to detail.
- Excellent written and verbal communication skills. Thrives in a fast-paced, collaborative, interdisciplinary team setting.
- 4+ years of relevant biotech or pharmaceutical industry experience in oncology drug discovery and development.
Preferred Skills
- Hands-on experience with humanized mouse models is desirable.
- Familiarity with multiomics analyses and integrating computational insights into experimental designs.
Requirements
- Ph.D. in immunology, cancer biology, or a related discipline
- Deep expertise in tumor immunology, immuno-oncology biomarkers, and/or immunotherapy
- Proven track record of research excellence, evidenced by high-impact publications
- Expertise in in vivo model design to evaluate efficacy and mechanisms of action of therapeutic agents and enable biomarker discovery
- Strong technical expertise in immunology techniques including multi-parameter flow cytometric analyses, primary human cellular/tissue-based functional assays, cell biology and molecular biology
- Strong problem-solving skills and ability to independently oversee scientific projects
- Excellent written and verbal communication skills
- 4+ years of relevant biotech or pharmaceutical industry experience in oncology drug discovery and development
Benefits
- Competitive cash compensation
- Robust equity awards
- Strong benefits
- Learning and development opportunities
Company overview
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies for RAS-addicted cancers. The company is pioneering a new class of therapeutics that target oncogenic RAS mutations, which are among the most common drivers of human cancers. Revolution Medicines employs a unique approach to drug discovery, leveraging deep insights into RAS biology to develop small molecule inhibitors that can address previously undruggable targets. Their pipeline includes multiple clinical-stage candidates designed to inhibit various RAS pathway mutations, with a particular focus on KRAS G12C and other RAS variants. The company's scientific platform combines structural biology, medicinal chemistry, and computational approaches to design highly selective inhibitors. Revolution Medicines aims to transform cancer treatment by developing therapies that can overcome resistance mechanisms and provide durable clinical benefits for patients with RAS-driven malignancies. Their research represents a significant advancement in the field of targeted cancer therapy, addressing one of the most challenging areas in oncology drug development.